Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.48 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 3/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28715942 | 0.84 | MAPT (0.49) | ADRB1SIRT6HTR2CMAPTCYP1A2 | |
| SCHEMBL7364719 | 0.80 | GRM5 (0.43) | MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1127150 | 0.77 | HTR2C (0.53) | ADRB1HTR2CHTR6 | |
| SCHEMBL14377204 | 0.77 | MEN1 (0.43) | MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL27786900 | 0.76 | ALDH1A1 (0.39) | ADRB1SIRT6HTR2CMAPT | |
| SCHEMBL8589619 | 0.75 | ADRB1 (0.61) | ADRB1SIRT6HTR2CCYP1A2CYP2C9 | |
| SCHEMBL2898307 | 0.74 | CYP1A2 (0.75) | MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL8566372 | 0.73 | ALDH1A1 (0.47) | MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL907889 | 0.72 | ALDH1A1 (0.54) | ADRB1SIRT6MAPTCYP1A2CYP2C19 | |
| SCHEMBL29682804 | 0.72 | MAPT (0.49) | ADRB1SIRT6HTR2CMAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6864261-B2 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2005-03-08 | — | — | US | disclosed |
| US-20040053914-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2004-03-18 | — | — | US | disclosed |
| WO-2003093236-A1 | 1-(PYRID-2-YL)-PIPERAZINE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR INHIBITOR | EURO-CELTIQUE, S.A. (LU) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053914-A1 | Therapeutic agents useful for treating pain | SMN1; SMN2, OPRM1, PSEN1 | ADRB1 519/4885SIRT6 3315/4885HTR2C 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.